Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 1,196 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,196 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the completion of the transaction, the insider now directly owns 110,695 shares in the company, valued at approximately $13,085,255.95. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 22nd, Solomon Moshkevich sold 256 shares of Natera stock. The stock was sold at an average price of $120.07, for a total value of $30,737.92.

Natera Stock Up 1.6 %

Shares of NASDAQ:NTRA traded up $1.99 during midday trading on Wednesday, reaching $126.73. The company had a trading volume of 794,882 shares, compared to its average volume of 1,316,621. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average price is $123.31 and its 200 day moving average price is $111.82. The stock has a market cap of $15.67 billion, a PE ratio of -51.71 and a beta of 1.53. Natera, Inc. has a 1-year low of $37.67 and a 1-year high of $133.54.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business’s revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.97) earnings per share. Research analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently bought and sold shares of the business. Marks Group Wealth Management Inc acquired a new position in Natera during the third quarter worth approximately $206,000. Leeward Financial Partners LLC acquired a new position in shares of Natera in the third quarter valued at approximately $215,000. QRG Capital Management Inc. acquired a new position in shares of Natera in the third quarter valued at approximately $671,000. Harbor Capital Advisors Inc. grew its position in shares of Natera by 261.2% in the third quarter. Harbor Capital Advisors Inc. now owns 18,124 shares of the medical research company’s stock valued at $2,301,000 after purchasing an additional 13,106 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC acquired a new position in shares of Natera in the third quarter valued at approximately $453,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on NTRA shares. Stephens reaffirmed an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Friday, October 25th. Canaccord Genuity Group raised their price objective on Natera from $145.00 to $150.00 and gave the stock a “buy” rating in a research note on Tuesday. Leerink Partners raised their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Sanford C. Bernstein lifted their price target on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $125.69.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.